INTRODUCTION

Assisted reproductive techniques (ARTs) result in a deficient luteal phase, requiring the administration of intramuscular, intravaginal or oral exogenous progesterone. Dydrogesterone, an oral retroprogesterone with good bioavailability, has been used in assisted reproductive cycles with outcomes that are comparable to those of vaginal or intramuscular progesterone. However, there are limited reviews on its use for luteal phase support in ARTs, in terms of pregnancy outcomes and associated fetal anomalies. This study aimed to review the live birth rates and associated fetal anomalies of women who were given dydrogesterone for luteal phase support in assisted reproductive cycles at a tertiary hospital in Singapore.

METHODS

This retrospective descriptive study included 1,050 women who underwent in vitro fertilisation/intracytoplasmic sperm injection at the Centre for Assisted Reproduction of Singapore General Hospital between 2000 and 2011. The women were given dydrogesterone for luteal phase support. The main outcome measures were rates of pregnancy, live birth, miscarriage and fetal anomalies.

RESULTS

The pregnancy and live birth rates were 34.7% and 27.7%, respectively. Among those who achieved pregnancy, 17.0% miscarried, 0.8% had ectopic pregnancies and 0.3% had molar pregnancies. Fetal anomalies were detected in 1.9% of pregnancies, all of which were terminated by choice.

CONCLUSION

Since the outcomes of dydrogesterone are comparable to those of intramuscular and vaginal progesterone, it is a reasonable option to provide luteal phase support for women who are uncomfortable with injections or vaginal insertions. Randomised controlled studies are needed to determine the optimal dosage of dydrogesterone for luteal phase support in ARTs.

Keywords: dydrogesterone, fetal anomalies, live birth, luteal phase support, pregnancy
An overview of birth defects reported from 1977 to 2005 showed that the use of dydrogesterone during pregnancy was not associated with congenital malformations. However, there are limited reviews on fetal anomalies associated with the use of dydrogesterone for luteal phase support in ARTs. Thus, the present study aimed to review the pregnancy outcomes, namely the live birth rates and incidence of fetal anomalies, of a large cohort of women who were given dydrogesterone for luteal phase support in *in vitro* fertilisation (IVF) at a tertiary centre in Singapore.

**METHODS**

This was a retrospective study conducted at the Centre for Assisted Reproduction in Singapore General Hospital (SGH), a tertiary centre in Singapore. The study was approved by SingHealth’s Centralised Institutional Review Board. Women who underwent fertility treatment in SGH from 2000 to 2011 were identified from the hospital database. The inclusion criteria were women who had undergone a fresh IVF/intracytoplasmic sperm injection (ICSI) cycle (non-donor cycle) and received oral dydrogesterone for luteal phase support. Women who were given progesterone intramuscularly or vaginally and those who were lost to follow-up or delivered overseas were excluded from the study. The final sample size was 1,050.

Each woman in the study underwent a tailored stimulation programme, using either an agonist or antagonist protocol, depending on the cause of their subfertility. Ovarian follicular development was monitored using transvaginal ultrasonography from Day 6 of stimulation. When three follicles had reached a maximal diameter of 18 mm, 10,000 IU hCG (Profasi; Serono, Geneva, Switzerland) was injected subcutaneously. Oocytes were retrieved transvaginally under ultrasonography-guidance 34–36 hours after hCG injection. Subsequently, either IVF or ICSI was performed, depending on the quality of the semen sample of the male partner. A maximum of three embryos were transferred on either Day 2 or Day 3 after retrieval, based on the quality of the embryos. Luteal phase support with dydrogesterone 10 mg three times a day was started on the day of oocyte retrieval and continued till the 12th week of pregnancy.

Outcome measures were rates of pregnancy, miscarriage, live births and fetal anomalies. A viable pregnancy was defined as the presence of ultrasonography evidence of a fetal pole with fetal heart activity at six weeks. Miscarriage was documented when there was ultrasonography evidence of an intrauterine gestation sac > 20 mm without a fetal pole and a crown rump length > 6 mm with absent fetal heart activity, or any other signs of pregnancy loss at < 24 weeks of gestation. A live delivery at or after 24 weeks of gestation was counted as a live birth. First trimester screening (FTS) for trisomy 13, 18 and 21 was performed between 11 and 14 weeks of gestation, and fetal anomaly imaging was performed between 18 and 20 weeks of gestation. The women were offered amniocentesis or chorionic villi sampling if their FTS was returned as ‘high risk’ and if structural anomalies were detected in the fetal anomaly images. All babies were assessed by neonatologists at birth for gross anomalies.

**RESULTS**

The sample population consisted of 1,050 women aged 21–45 (mean age 35) years. Table I shows the outcomes of the 1,050 women who underwent IVF/ICSI and received dydrogesterone for luteal phase support. Of these, 34.7% achieved pregnancy, while the remaining 65.3% failed to achieve pregnancy. Among those who achieved pregnancy, 79.9% delivered successfully, 17.0% miscarried spontaneously, 0.8% had ectopic pregnancies, 0.3% had molar pregnancies and 1.9% terminated their pregnancies. All the women who terminated their pregnancies did so due to the presence of fetal anomalies detected on fetal anomaly imaging. Among the 291 live births, none had any gross anomalies at birth detected by the neonatologists. Table II lists the types of fetal anomalies that were detected among the women who achieved pregnancy.

**DISCUSSION**

In ARTs, the use of progesterone in routine luteal phase support has achieved significantly higher pregnancy rates than placebos. Progesterone is currently available in intramuscular, vaginal and oral formulations, with the former two being the more widely used formulations. Intramuscular progesterone is rapidly absorbed by the body and reaches high serum concentration within two hours. Vaginal progesterone is available as tablet, gel or cream preparations. Compared to intramuscular progesterone, vaginal progesterone is cleared more rapidly from the body’s circulatory system and requires higher dosages to achieve serum progesterone levels that are equivalent to that of a physiological luteal phase. In the Cochrane review of studies that compared the use of intramuscular and vaginal progesterone for luteal phase support, no significant differences

**Table I. Outcomes of the women in the sample population (n = 1,050).**

<table>
<thead>
<tr>
<th>Outcome</th>
<th>No. (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Did not achieve pregnancy</td>
<td>686 (65.3)</td>
</tr>
<tr>
<td>Achieved pregnancy</td>
<td>364 (34.7)</td>
</tr>
<tr>
<td>Live birth</td>
<td>291 (27.7)</td>
</tr>
<tr>
<td>Spontaneous miscarriage</td>
<td>62 (5.9)</td>
</tr>
<tr>
<td>Ectopic pregnancy</td>
<td>3 (0.3)</td>
</tr>
<tr>
<td>Molar pregnancy</td>
<td>1 (0.1)</td>
</tr>
<tr>
<td>Termination of pregnancy</td>
<td>7 (0.7)</td>
</tr>
</tbody>
</table>

**Table II. Types of fetal anomalies detected among the women who achieved pregnancy (n = 364).**

<table>
<thead>
<tr>
<th>Type of fetal anomaly</th>
<th>No. (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anencephaly</td>
<td>1 (0.3)</td>
</tr>
<tr>
<td>Renal agenesis</td>
<td>1 (0.3)</td>
</tr>
<tr>
<td>Arthrogryposis</td>
<td>1 (0.3)</td>
</tr>
<tr>
<td>Cleft lip/palate</td>
<td>1 (0.3)</td>
</tr>
<tr>
<td>Exomphalos</td>
<td>1 (0.3)</td>
</tr>
<tr>
<td>Complex heart disease</td>
<td>1 (0.3)</td>
</tr>
<tr>
<td>Sacrococcygeal teratoma</td>
<td>1 (0.3)</td>
</tr>
<tr>
<td>Total</td>
<td>7 (1.9)</td>
</tr>
</tbody>
</table>
were found between the two in terms of live birth and clinical pregnancy rates. While vaginal progesterone offers women a painless alternative, side effects such as vaginal irritation and discharge have been reported.

Among the various formulations of progesterone available, the ease of administration of oral progesterone relative to vaginal or intramuscular progesterone is undeniable. However, the bioavailability of oral progesterone is only 10% that of intramuscular progesterone due to the hepatic first-pass effect. Dydrogesterone, a retro isomer of progesterone, has an additional double bond between carbon-6 and carbon-7. Compared to progesterone, which has an almost ‘flat’ molecular structure, dydrogesterone is bent due to a switch of the methyl group at carbon-10 from a beta position to an alpha position, and a switch of the hydrogen at carbon-9 from an alpha position to a beta position. The enhanced configuration of dydrogesterone results in its increased stability and, hence, higher bioavailability (i.e. 28%) as compared to oral progesterone. A few small studies that investigated the effectiveness of dydrogesterone in ARTs have found dydrogesterone to be effective for luteal phase support when compared to other types of progesterone. 10–11 Chakravarty et al10 and Ganesh et al11 reported pregnancy rates of 22.8% and 28.7%, respectively, when dydrogesterone 20 mg per day was used for luteal phase support. Salehpour et al reported a pregnancy rate of 25% when dydrogesterone at 40 mg per day was used for luteal phase support in ARTs. 11 Three of these aforementioned studies did not find any significant differences between the pregnancy rates of women using dydrogesterone and those of women using vaginal progesterone. Only the study by Chakravarty et al reported on the rate of live births among the women using dydrogesterone; 19 out of 79 women (24.1%) on dydrogesterone delivered successfully. This live birth rate is similar to the rate of 27.7% found in the present study, which is also comparable to the average live birth rate of couples who conceive with ARTs in Singapore (i.e. 30%).

The rate of miscarriage for all pregnancies is estimated to range from 15% to 20%. A retrospective analysis of all pregnancies conceived via ARTs in SGH from 1998 to 2003 revealed a miscarriage rate of 19.9%. The miscarriage rate in the present study was 17.0%, which is within the miscarriage rate for spontaneous pregnancies and is also the average miscarriage rate for ARTS done in our centre. Recurrent miscarriages, defined as three or more consecutive early pregnancy losses, affect 1% of couples. A Cochrane review of studies that compared the effect of progesterone treatment on women with recurrent miscarriages to that of placebos or no treatment found that progesterone treatment significantly reduced miscarriage rates.

In addition to progesterone’s role in luteal phase support, studies have suggested that progesterone may have a role in promoting a shift toward anti-inflammatory cytokines, which help prevent maternal rejection of the immunologically foreign fetus. In normal pregnancies, progesterone-induced blocking factor is synthesised by activated lymphocytes in the presence of progesterone; this promotes the dominance of anti-inflammatory Th2 cytokines over inflammatory Th1 cytokines. Dydrogesterone binds almost exclusively to progesterone receptors, and since it is structurally similar to endogenous progesterone, it has been shown to induce a shift toward anti-inflammatory cytokines. In a randomised placebo-controlled trial that investigated the effect of dydrogesterone treatment on pregnancy outcomes among women with recurrent miscarriages, the risk of repeat miscarriage was found to be significantly higher (2.4 times) in the placebo group.

A study that reviewed birth defects reported from 1977 to 2005 was not able to find any conclusive association between the use of dydrogesterone during pregnancy and congenital birth defects, due to the diversity of birth defects found. Similarly, there was no dominant type of fetal anomaly or any obvious pattern of abnormality among the seven cases of fetal anomalies detected in the present study. The fetal anomaly rate of 1.9% in our study was within the range reported in a meta-analysis of 19 studies, in which the rate of major congenital anomaly was 0%–9.5% for the IVF group, 1.1%–9.7% for the ICSI group and 0%–6.9% for the control group. Given the lack of observed association between dydrogesterone and the occurrence of birth defects, as well as the evidence that dydrogesterone has a protective effect against recurrent miscarriages, it is reasonable for dydrogesterone to be considered a viable option for luteal phase support in ARTs. One limitation of the present study was the lack of a control group, which prevented a comparison between the outcomes of intramuscular and vaginal progesterone use in the sample population.

In conclusion, while there has not been any evidence favouring a specific route of administration of progesterone for luteal phase support in ARTs in terms of outcomes, the oral route is favoured by women due to its ease of administration. The present study has shown that reasonable pregnancy and live birth rates can be achieved using dydrogesterone for luteal phase support in a large cohort of women. We did not observe any increased risk of fetal anomalies or miscarriages with the use of dydrogesterone in IVF. Thus, dydrogesterone can be considered for women who are not comfortable with injections or vaginal applications. Although current studies have evaluated the efficacy of dydrogesterone for luteal phase support with dosages ranging from 20 mg to 40 mg per day, none have examined the effect of different dosages of dydrogesterone on ART outcomes. Future large-scale, randomised controlled trials should be conducted to identify the optimal dosage of dydrogesterone for luteal phase support in ARTs.

REFERENCES


